当前位置: 首页 >> 检索结果
61. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
作者: Milind Y Desai.;Kathy Wolski.;Anjali Owens.;Jeffrey B Geske.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Paul C Cremer.;Neal K Lakdawala.;Albree Tower-Rader.;David Fermin.;Srihari S Naidu.;Nicholas G Smedira.;Hartzell Schaff.;Zhiqun Gong.;Lana Mudarris.;Kathy Lampl.;Amy J Sehnert.;Steven E Nissen.; .
来源: Circulation. 2025年151卷19期1378-1390页
In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128.
62. Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).
作者: Yugo Yamashita.;Takeshi Morimoto.;Nao Muraoka.;Wataru Shioyama.;Ryuki Chatani.;Tatsuhiro Shibata.;Yuji Nishimoto.;Yoshito Ogihara.;Kosuke Doi.;Maki Oi.;Taro Shiga.;Daisuke Sueta.;Kitae Kim.;Yasuhiro Tanabe.;Norimichi Koitabashi.;Takuma Takada.;Satoshi Ikeda.;Hitoshi Nakagawa.;Kengo Tsukahara.;Masaaki Shoji.;Jiro Sakamoto.;Shinji Hisatake.;Yutaka Ogino.;Masashi Fujita.;Naohiko Nakanishi.;Tomohiro Dohke.;Seiichi Hiramori.;Ryuzo Nawada.;Kazuhisa Kaneda.;Koh Ono.;Takeshi Kimura.; .
来源: Circulation. 2025年151卷9期589-600页
The optimal duration of anticoagulation therapy for patients with cancer and acute low-risk pulmonary embolism (PE) is clinically relevant, but evidence is lacking. Prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding.
63. Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial.
作者: Scott A Hubers.;Sherry L Benike.;Bradley K Johnson.;Paul M McKie.;Christopher Scott.;Horng H Chen.
来源: Circ Heart Fail. 2024年17卷12期e011761页
Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF). Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response. The aim of this study was to determine whether B-type natriuretic peptide (BNP) alone or in combination with PDEV inhibition improves renal function and increases urinary sodium and cGMP excretion in acute HF.
64. Exercise Training in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction: A Randomized Clinical Trial.
作者: Helga Lillian Gudmundsdottir.;Anna Axelsson Raja.;Kasper Rossing.;Hanne Rasmusen.;Martin Snoer.;Lars Juel Andersen.;Rikke Gottlieb.;Alex Hørby Christensen.;Henning Bundgaard.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷2期132-144页
Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience reduced exercise capacity. Physical training improves exercise capacity in these patients, but whether the underlying effects of exercise are a result of central hemodynamic or peripheral improvement is unclear. This study assessed whether exercise training reduces left ventricular filling pressure measured during exercise in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction.
65. Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial.
作者: Alexander C Fanaroff.;Daniel M Wojdyla.;Christopher B Granger.;Shaun G Goodman.;Ronald S Aronson.;Stephan Windecker.;Roxana Mehran.;John H Alexander.;Renato D Lopes.
来源: Circ Cardiovasc Interv. 2024年17卷11期e013596页
In the AUGUSTUS trial (An Open-Label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), the combination of dual antiplatelet therapy plus oral anticoagulation increased the risk of bleeding without reducing ischemic events compared with a P2Y12 inhibitor plus oral anticoagulation among patients with atrial fibrillation and acute coronary syndrome or elective percutaneous coronary intervention. However, AUGUSTUS enrolled patients up to 14 days after acute coronary syndrome or percutaneous coronary intervention, and there may be a benefit to dual antiplatelet therapy plus oral anticoagulation early after an ischemic event.
66. Impact of a Chronic Total Occlusion on Outcomes After FFR-Guided PCI or Coronary Bypass Surgery: A FAME 3 Substudy.
作者: Hisao Otsuki.;Kuniaki Takahashi.;Frederik M Zimmermann.;Kreton Mavromatis.;Adel Aminian.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Philip MacCarthy.;Nils Witt.;Yuhei Kobayashi.;Tatsunori Takahashi.;Y Joseph Woo.;Alan C Yeung.;Bernard De Bruyne.;Nico H J Pijls.;William F Fearon.; .
来源: Circ Cardiovasc Interv. 2024年17卷11期e014300页
The clinical impact of a chronic total occlusion (CTO) in patients with 3-vessel coronary artery disease undergoing fractional flow reserve-guided percutaneous coronary intervention (PCI) with current-generation drug-eluting stents or coronary artery bypass grafting (CABG) is unclear.
67. Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial.
作者: Hayley T Dillon.;Nicholas J Saner.;Tegan Ilsley.;David S Kliman.;Stephen J Foulkes.;Christian J Brakenridge.;Andrew Spencer.;Sharon Avery.;Piet Claus.;David W Dunstan.;Robin M Daly.;Steve F Fraser.;Neville Owen.;Brigid M Lynch.;Bronwyn A Kingwell.;Andre La Gerche.;Erin J Howden.
来源: Circulation. 2025年151卷4期292-308页
Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be complicated by cardiac dysfunction and exercise intolerance impacting quality of life and longevity. We conducted a randomized controlled trial testing whether a multicomponent activity intervention could attenuate reductions in cardiorespiratory fitness and exercise cardiac function (co-primary end points) in adults undergoing allo-SCT.
68. Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial.
作者: Wissam A Jaber.;Carin F Gonsalves.;Stefan Stortecky.;Samuel Horr.;Orestis Pappas.;Ripal T Gandhi.;Keith Pereira.;Jay Giri.;Sameer J Khandhar.;Khawaja Afzal Ammar.;David M Lasorda.;Brian Stegman.;Lucas Busch.;David J Dexter.;Ezana M Azene.;Nikhil Daga.;Fakhir Elmasri.;Chandra R Kunavarapu.;Mark E Rea.;Joseph S Rossi.;Joseph Campbell.;Jonathan Lindquist.;Adam Raskin.;Jason C Smith.;Thomas M Tamlyn.;Gabriel A Hernandez.;Parth Rali.;Torrey R Schmidt.;Jeffrey T Bruckel.;Juan C Camacho.;Jun Li.;Samy Selim.;Catalin Toma.;Sukhdeep Singh Basra.;Brian A Bergmark.;Bhavraj Khalsa.;David M Zlotnick.;Jordan Castle.;David J O'Connor.;C Michael Gibson.; .
来源: Circulation. 2025年151卷5期260-273页
There are a lack of randomized controlled trial data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism.
69. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease.
作者: Michael J Foley.;Christopher A Rajkumar.;Fiyyaz Ahmed-Jushuf.;Florentina Simader.;Shayna Chotai.;Henry Seligman.;Krzysztof Macierzanka.;John R Davies.;Thomas R Keeble.;Peter O'Kane.;Peter Haworth.;Helen Routledge.;Tushar Kotecha.;Gerald Clesham.;Rupert Williams.;Jehangir Din.;Sukhjinder S Nijjer.;Nick Curzen.;Manas Sinha.;Ricardo Petraco.;James Spratt.;Sayan Sen.;Graham D Cole.;Frank E Harrell.;James P Howard.;Darrel P Francis.;Matthew J Shun-Shin.;Rasha Al-Lamee.; .
来源: Circulation. 2025年151卷3期202-214页
ORBITA-2 (the Placebo-Controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina) provided evidence for the role of percutaneous coronary intervention (PCI) for angina relief in stable coronary artery disease. Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are often used to guide PCI; however, their ability to predict placebo-controlled angina improvement is unknown.
70. Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.
作者: Elric Zweck.;Christian Hassager.;Rasmus P Beske.;Lisette O Jensen.;Hans Eiskjær.;Norman Mangner.;Amin Polzin.;P Christian Schulze.;Carsten Skurk.;Peter Nordbeck.;Peter Clemmensen.;Vasileios Panoulas.;Sebastian Zimmer.;Andreas Schäfer.;Malte Kelm.;Thomas Engstrøm.;Lene Holmvang.;Anders Junker.;Henrik Schmidt.;Christian J Terkelsen.;Axel Linke.;Ralf Westenfeld.;Jacob E Møller.; .
来源: Circulation. 2024年150卷25期1990-2003页
In DanGer Shock (the Danish-German Cardiogenic Shock trial), use of a microaxial flow pump (mAFP) in patients with ST-segment-elevation myocardial infarction-related cardiogenic shock led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed.
71. Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
作者: Li Shen.;Pooja Dewan.;João Pedro Ferreira.;Jonathan W Cunningham.;Pardeep S Jhund.;Inder S Anand.;Alvin Chandra.;Lu-May Chiang.;Brian Claggett.;Akshay S Desai.;Jianjian Gong.;Carolyn S P Lam.;Martin P Lefkowitz.;Aldo P Maggioni.;Felipe Martinez.;Milton Packer.;Margaret M Redfield.;Jean L Rouleau.;Dirk J van Veldhuisen.;Faiez Zannad.;Michael R Zile.;Scott D Solomon.;John J V McMurray.
来源: Circulation. 2024年150卷24期1913-1927页
Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood.
72. Three-Year Outcomes Following TAVR in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients.
作者: Thomas Modine.;Didier Tchétché.;Nicolas M Van Mieghem.;G Michael Deeb.;Stanley J Chetcuti.;Steven J Yakubov.;Paul Sorajja.;Hemal Gada.;Mubashir Mumtaz.;Basel Ramlawi.;Tanvir Bajwa.;John Crouch.;Paul S Teirstein.;Neal S Kleiman.;Ayman Iskander.;Rodrigo Bagur.;Michael W A Chu.;Pierre Berthoumieu.;Arnaud Sudre.;Rik Adrichem.;Saki Ito.;Jian Huang.;Jeffrey J Popma.;John K Forrest.;Michael J Reardon.
来源: Circ Cardiovasc Interv. 2024年17卷11期e014018页
Transcatheter aortic valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis, but data are limited on younger, low-risk patients. This analysis compares outcomes in low-surgical-risk patients aged <75 years receiving TAVR versus surgery.
73. Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury.
作者: Stephen Duff.;Nicholas Wettersten.;Yu Horiuchi.;Dirk J van Veldhuisen.;Sagar Raturi.;Ruairi Irwin.;Jean Maxime Côté.;Alan Maisel.;Joachim H Ix.;Patrick T Murray.
来源: Circ Heart Fail. 2024年17卷11期e011751页
Worsening renal function (WRF) is common in hospitalized patients being treated for acute heart failure. However, discriminating clinically significant WRF remains challenging. In patients hospitalized with acute heart failure, we evaluated if blood and urine biomarkers of cardiac and kidney dysfunction were associated with adverse outcomes.
74. Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial.
作者: Robert A Byrne.;Róisín Colleran.;J J Coughlan.;Rajiv Jauhar.;Luc Maillard.;Axel De Labriolle.;Michael Maeng.;Charles Croft.;Michael Brunner.;David Leistner.;Bernhard Zrenner.;Marc Kollum.;Karl-Ludwig Laugwitz.;Erion Xhepa.;Katharina Mayer.;Shqipdona Lahu.;Michael Joner.;Ajay Kirtane.;Roxana Mehran.;Mark Barakat.;Philip Urban.;Donald E Cutlip.;Adnan Kastrati.; .
来源: Circ Cardiovasc Interv. 2024年17卷10期e013735页
Patients with an indication for oral anticoagulation who undergo percutaneous coronary intervention require a combination of oral anticoagulation and antiplatelet therapy. The use of a coronary stent with a thromboresistant and pro-healing coating may allow an abbreviated duration of dual antiplatelet therapy (DAPT) without an increase in the risk of thromboembolic events.
75. Ablation Strategies for Repeat Procedures in Atrial Fibrillation Recurrences Despite Durable Pulmonary Vein Isolation: The Prospective Randomized ASTRO AF Multicenter Trial.
作者: Boris Schmidt.;Stefano Bordignon.;Andreas Metzner.;Philipp Sommer.;Daniel Steven.;Tilmann Dahme.;Matthias Busch.;Roland Richard Tilz.;David Schaack.;Andreas Rillig.;Christian Sohns.;Arian Sultan.;Karolina Weinmann-Emhardt.;Astrid Hummel.;Julia Vogler.;Thomas Fink.;Jakob Lueker.;Alexander Pott.;Christian Heeger.;K R Julian Chun.
来源: Circulation. 2024年150卷25期2007-2018页
Ablation strategies for patients with symptomatic atrial fibrillation and isolated pulmonary veins vary and their effects on arrhythmia recurrence remain unclear. A prospective randomized German multicenter trial sought to compare 2 ablation strategies in this patient cohort.
76. Comparison of Ultrathin- Versus Thin-Strut Stents in Patients With High Bleeding Risk PCI: Results From the COMPARE 60/80 HBR Trial: An Open-Label, Randomized, Controlled Trial.
作者: Pieter C Smits.;Pim A L Tonino.;Sjoerd H Hofma.;Jan-Peter van Kuijk.;Fabrizio Spano.;Amar Al Mafragi.;Ron Pisters.;Jawed Polad.;Kris Bogaerts.;Rohit M Oemrawsingh.;Valeria Paradies.
来源: Circ Cardiovasc Interv. 2024年17卷10期e014042页
No randomized data exist on ultrathin-strut stents in patients at high bleeding risk (HBR) undergoing an abbreviated dual antiplatelet therapy after coronary stenting. The aim of this study was to compare the safety and effectiveness of the ultrathin-strut biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the thin-strut biodegradable-polymer sirolimus-eluting Ultimaster Tansei stent in patients at HBR with abbreviated dual antiplatelet therapy after stenting.
77. Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF.
作者: Misato Chimura.;Mark C Petrie.;Morten Schou.;Felipe A Martinez.;Alasdair D Henderson.;Brian L Claggett.;Akshay S Desai.;Peter Kolkhof.;Prabhakar Viswanathan.;Andrea Lage.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Katja Rohwedder.;Katharina Mueller.;Adriaan A Voors.;Faiez Zannad.;Bertram Pitt.;Muthiah Vaduganathan.;Pardeep S Jhund.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2024年17卷11期e012437页
Finerenone improves outcomes in patients with heart failure and mildly reduced or preserved ejection fraction. It is important to understand the efficacy and safety of finerenone in these patients according to age.
78. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.
作者: Kieran F Docherty.;Alasdair D Henderson.;Pardeep S Jhund.;Brian L Claggett.;Akshay S Desai.;Katharina Mueller.;Prabhakar Viswanathan.;Andrea Scalise.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Faiez Zannad.;Bertram Pitt.;Muthiah Vaduganathan.;Scott D Solomon.;John J V McMurray.
来源: Circulation. 2025年151卷1期45-58页
The effects of treatments for heart failure (HF) may vary among patients according to left ventricular ejection fraction (LVEF). In FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure), the nonsteroidal mineralocorticoid receptor antagonist finerenone reduced the risk of cardiovascular death and total worsening HF events in patients with HF with mildly reduced or preserved ejection fraction. We examined the effect of finerenone according to LVEF in FINEARTS-HF.
79. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
作者: Muthiah Vaduganathan.;Brian L Claggett.;Ian J Kulac.;Zi Michael Miao.;Akshay S Desai.;Pardeep S Jhund.;Alasdair D Henderson.;Meike Brinker.;James Lay-Flurrie.;Prabhakar Viswanathan.;Markus Florian Scheerer.;Andrea Lage.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Faiez Zannad.;Bertram Pitt.;John J V McMurray.;Scott D Solomon.
来源: Circulation. 2025年151卷2期149-158页
Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and the nonsteroidal mineralocorticoid receptor antagonist finerenone have both been shown to reduce the risk of cardiovascular events in this population, but the effects of their combined use are not known.
80. Performance and Safety of the Extravascular Implantable Cardioverter Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study.
作者: Paul Friedman.;Francis Murgatroyd.;Lucas V A Boersma.;Jaimie Manlucu.;Bradley P Knight.;Nicolas Clémenty.;Christophe Leclercq.;Anish Amin.;Béla Merkely.;Ulrika Maria Birgersdotter-Green.;Joseph Yat Sun Chan.;Mauro Biffi.;Reinoud Elwin Knops.;Gregory Engel.;Ignacio Muñoz Carvajal.;Laurence M Epstein.;Venkata Sagi.;Jens Brock Johansen.;Maciej Sterliński.;Clemens Steinwender.;Troy Hounshell.;Richard Abben.;Amy E Thompson.;Yan Zhang.;Christopher Wiggenhorn.;Sarah Willey.;Ian Crozier.; .
来源: Circulation. 2025年151卷4期322-332页
Substernal lead placement of the extravascular implantable cardioverter defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous implantable cardioverter defibrillators and effective anti-tachycardia pacing (ATP) while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term experience has yet to be published. Our aim was to report the performance and safety of the EV ICD system throughout the study.
|